Our initial CCR investigations of triple negative breast cancer [27,28] prompted us to examine all newly diagnosed breast cancer patients using ER/PR/HER2 subtype as a surrogate for the molecular classification [6,7]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.